The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Updated analysis of MAIA: D-Rd continues to beat Rd in transplant-ineligible NDMM
Nizar Bahlis, MD, University of Calgary, Calgary, AB, Canada, gives an update on the MAIA trial (NCT02252172), which compared the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (MM) who are not candidates for high dose chemotherapy and autologous stem cell transplant. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
